Table 2.
Adiponectin, resistin and glucose levels in the CSF from WT and APP/PSN1 animals treated with HFD plus adiponectin or resistin.
| WT | WT+HFD | WT+HFD+ApN | WT+HFD+Resistin | |
|---|---|---|---|---|
| Adiponectin (ng/mL) | 14.5 ± 2.1 | 3.3 ± 0.5** | 10.8 ± 0.9& | 3 ± 0.6** |
| Resistin (pg/mL) | 9.6 ± 2.7 | 34.5 ± 3** | 28 ± 2.8** | 54 ± 4*& |
| Glucose (mg/dl) | 58 ± 3.6 | 93 ± 5*** | 64 ± 3.5&&& | 96 ± 3*** |
| APP/PSN1 | APP/PSN1+HFD | APP/PSN1+HFD+ApN | APP/PSN1+HFD+Resistin | |
| Adiponectin (ng/mL) | 12.6 ± 0.7 | 3.6 ± 0.4* | 10 ± 0.4& | 4 ± 0.8* |
| Resistin (pg/mL) | 12.3 ± 1.5 | 24.2 ± 1.3* | 21 ± 1.1* | 40 ± 2.9*& |
| Glucose (mg/dl) | 71 ± 3.5 | 107 ± 4.3*** | 67 ± 4.8&&& | 100 ± 5.8** |
*p < 0.05 and **p < 0.01, compared with WT or APP/PSN1 control groups; &p < 0.05, compared with WT or APP/PSN1 + HFD group.